Generic Coreg To Launch Immediately Following FDA Approval
Executive Summary
The first generic versions of GlaxoSmithKline's blockbuster heart failure medication Coreg (carvedilol) will launch immediately following FDA's Sept. 5 approval of several ANDAs for the beta blocker
You may also be interested in...
GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
GSK Bolsters Cardiovascular Portfolio With Acquisition Of Reliant
GlaxoSmithKline's acquisition of Reliant for $1.65 billion will give the U.K. drug maker access to a growing cardiovascular drug in the U.S., Lovaza. The drug will complement GSK's existing CV portfolio, including the hypertension drug Coreg CR
Avandia Continues To Take Its Toll; GSK Restructuring Will Cut $1.5 Bil., Jobs
Due in part to plummeting Avandia sales, GlaxoSmithKline will cut $1.5 billion in costs through a restructuring program targeting sales and manufacturing, the firm announced in a third quarter sales and earnings call Oct. 24